174 related articles for article (PubMed ID: 24695110)
21. Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphomas.
Amara K; Trimeche M; Ziadi S; Laatiri A; Hachana M; Korbi S
Ann Oncol; 2008 Oct; 19(10):1774-86. PubMed ID: 18539616
[TBL] [Abstract][Full Text] [Related]
22. Correlation between the single-site CpG methylation and expression silencing of the XAF1 gene in human gastric and colon cancers.
Zou B; Chim CS; Zeng H; Leung SY; Yang Y; Tu SP; Lin MC; Wang J; He H; Jiang SH; Sun YW; Yu LF; Yuen ST; Kung HF; Wong BC
Gastroenterology; 2006 Dec; 131(6):1835-43. PubMed ID: 17087954
[TBL] [Abstract][Full Text] [Related]
23. Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma.
Wong CM; Ng YL; Lee JM; Wong CC; Cheung OF; Chan CY; Tung EK; Ching YP; Ng IO
Hepatology; 2007 May; 45(5):1129-38. PubMed ID: 17464989
[TBL] [Abstract][Full Text] [Related]
24. Correlation between promoter hypermethylation of GSTP1 and response to chemotherapy in diffuse large B cell lymphoma.
Nakamichi I; Tomita Y; Zhang B; Sugiyama H; Kanakura Y; Fukuhara S; Hino M; Kanamaru A; Ogawa H; Aozasa K
Ann Hematol; 2007 Aug; 86(8):557-64. PubMed ID: 17508213
[TBL] [Abstract][Full Text] [Related]
25. Promoter hypermethylation of PTPL1, PTPN6, DAPK, p16 and 5-azacitidine inhibits growth in DLBCL.
Wang W; Wang J; Li Z; Zhu M; Zhang Z; Wang Y; Jing H
Oncol Rep; 2016 Jan; 35(1):139-46. PubMed ID: 26498513
[TBL] [Abstract][Full Text] [Related]
26. Promoter methylation of p16, Runx3, DAPK and CHFR genes is frequent in gastric carcinoma.
Hu SL; Kong XY; Cheng ZD; Sun YB; Shen G; Xu WP; Wu L; Xu XC; Jiang XD; Huang DB
Tumori; 2010; 96(5):726-33. PubMed ID: 21302620
[TBL] [Abstract][Full Text] [Related]
27. Hypermethylation of XIAP-associated factor 1, a putative tumor suppressor gene from the 17p13.2 locus, in human gastric adenocarcinomas.
Byun DS; Cho K; Ryu BK; Lee MG; Kang MJ; Kim HR; Chi SG
Cancer Res; 2003 Nov; 63(21):7068-75. PubMed ID: 14612497
[TBL] [Abstract][Full Text] [Related]
28. Promoter hypermethylation of the DNA-repair gene O6-methylguanine-DNA methyltransferase and p53 mutation in diffuse large B-cell lymphoma.
Hiraga J; Kinoshita T; Ohno T; Mori N; Ohashi H; Fukami S; Noda A; Ichikawa A; Naoe T
Int J Hematol; 2006 Oct; 84(3):248-55. PubMed ID: 17050200
[TBL] [Abstract][Full Text] [Related]
29. Impaired expression and promotor hypermethylation of O6-methylguanine-DNA methyltransferase in retinoblastoma tissues.
Choy KW; Pang CP; To KF; Yu CB; Ng JS; Lam DS
Invest Ophthalmol Vis Sci; 2002 May; 43(5):1344-9. PubMed ID: 11980845
[TBL] [Abstract][Full Text] [Related]
30. Hypermethylation of the death-associated protein kinase CpG island in canine B-cell lymphoid tumors.
Sato M; Mochizuki H; Goto-Koshino Y; Fujiwara-Igarashi A; Takahashi M; Fujino Y; Ohno K; Tsujimoto H
Vet Immunol Immunopathol; 2014 Oct; 161(3-4):222-31. PubMed ID: 25193469
[TBL] [Abstract][Full Text] [Related]
31. Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma.
Byun DS; Lee MG; Chae KS; Ryu BG; Chi SG
Cancer Res; 2001 Oct; 61(19):7034-8. PubMed ID: 11585730
[TBL] [Abstract][Full Text] [Related]
32. Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), a gene encoding an inhibitor of matrix metalloproteinases in human glioma cells.
Konduri SD; Srivenugopal KS; Yanamandra N; Dinh DH; Olivero WC; Gujrati M; Foster DC; Kisiel W; Ali-Osman F; Kondraganti S; Lakka SS; Rao JS
Oncogene; 2003 Jul; 22(29):4509-16. PubMed ID: 12881707
[TBL] [Abstract][Full Text] [Related]
33. MGMT methylation in diffuse large B-cell lymphoma: validation of quantitative methylation-specific PCR and comparison with MGMT protein expression.
Uccella S; Cerutti R; Placidi C; Marchet S; Carnevali I; Bernasconi B; Proserpio I; Pinotti G; Tibiletti MG; Furlan D; Capella C
J Clin Pathol; 2009 Aug; 62(8):715-23. PubMed ID: 19638543
[TBL] [Abstract][Full Text] [Related]
34. Associations between TFPI-2 methylation and poor prognosis in glioblastomas.
Vaitkienė P; Skiriutė D; Skauminas K; Tamašauskas A
Medicina (Kaunas); 2012; 48(7):345-9. PubMed ID: 23032906
[TBL] [Abstract][Full Text] [Related]
35. Loss of expression of ZAC/PLAGL1 in diffuse large B-cell lymphoma is independent of promoter hypermethylation.
Valleley EM; Cordery SF; Carr IM; MacLennan KA; Bonthron DT
Genes Chromosomes Cancer; 2010 May; 49(5):480-6. PubMed ID: 20175198
[TBL] [Abstract][Full Text] [Related]
36. [Potential mechanism and prognostic value of promoter methylation of PRDM1 gene in diffuse large B cell lymphoma].
Zhang XY; Ma ZP; Cui WL; Chen R; Glinaer A; Miao N; Li XX
Zhonghua Bing Li Xue Za Zhi; 2016 Dec; 45(12):831-837. PubMed ID: 28056297
[No Abstract] [Full Text] [Related]
37. Promoter hypermethylation of DNA damage response genes in hepatocellular carcinoma.
Li Z; Zhang H; Yang J; Hao T; Li S
Cell Biol Int; 2012 May; 36(5):427-32. PubMed ID: 21864295
[TBL] [Abstract][Full Text] [Related]
38. Genome-wide DNA methylation and RNA-seq analyses identify genes and pathways associated with doxorubicin resistance in a canine diffuse large B-cell lymphoma cell line.
Hsu CH; Tomiyasu H; Liao CH; Lin CS
PLoS One; 2021; 16(5):e0250013. PubMed ID: 33961622
[TBL] [Abstract][Full Text] [Related]
39. Low abundance of TFPI-2 by both promoter methylation and miR-27a-3p regulation is linked with poor clinical outcome in gastric cancer.
Geng G; Liu X; Xu A; Lu Z; Chen K; He J; Qi D; Yuan X
J Gene Med; 2020 May; 22(5):e3166. PubMed ID: 31984574
[TBL] [Abstract][Full Text] [Related]
40. Low Expression and Promoter Hypermethylation of the Tumour Suppressor SLIT2, are Associated with Adverse Patient Outcomes in Diffuse Large B Cell Lymphoma.
Mohamed G; Talima S; Li L; Wei W; Rudzki Z; Allam RM; Simmons W; Tao Q; Murray PG
Pathol Oncol Res; 2019 Jul; 25(3):1223-1231. PubMed ID: 30739251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
